Gilteritinib has been reported to maintain activity against secondary mutations in the TKD (D835Y) [30, 34], yet RAS mutations were a common mechanism of acquired resistance to gilteritinib in patients with FLT3-mutated AML [40]. The gene discussed is FLT3; the disease is acute myeloid leukemia.